dc.contributor.author |
Chalela Rengifo, Roberto José, 1985- |
dc.contributor.author |
Bellosillo Paricio, Beatriz |
dc.contributor.author |
Curull Serrano, Víctor |
dc.contributor.author |
Longarón Rozalen, Raquel |
dc.contributor.author |
Pascual Guàrdia, Sergi, 1979- |
dc.contributor.author |
Badenes Bonet, Diana, 1987- |
dc.contributor.author |
Arriola Aperribay, Edurne |
dc.contributor.author |
Sánchez-Font, Albert |
dc.contributor.author |
Pijuan Andujar, Lara |
dc.contributor.author |
Gea Guiral, Joaquim |
dc.date.accessioned |
2020-02-10T08:22:19Z |
dc.date.available |
2020-02-10T08:22:19Z |
dc.date.issued |
2019 |
dc.identifier.citation |
Chalela R, Bellosillo B, Curull V, Longarón R, Pascual-Guardia S, Badenes-Bonet D et al. EGFR and KRAS mutations in the non-tumoral lung. Prognosis in patients with adenocarcinoma. J Clin Med. 2019 Apr 17;8(4):529. DOI: 10.3390/jcm8040529 |
dc.identifier.issn |
2077-0383 |
dc.identifier.uri |
http://hdl.handle.net/10230/43531 |
dc.description.abstract |
Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutations observed in ADC can also be observed in the non-neoplastic lung tissue, as well as the short-term prognosis implications of this finding. Methods: Non-tumoral lung parenchyma specimens obtained during surgery from 47 patients with EGFR and/or KRAS abnormalities in their ADC tumors underwent similar genomic testing. Short-term outcomes were also recorded. Results: The same mutations were present in the tumor and the histologically normal tissue in 21.3% of patients (SM group). Although local recurrences were similar in both groups, distant metastases were more frequent in the former (60 vs. 5.4%, p < 0.001). Moreover, SM patients showed lower time-to-progression (8.5 vs. 11.7 months, p < 0.001) and disease-free survival (8.5 vs. 11.2 months, p < 0.001). COX regression showed a higher risk of progression or death (DFS) in the SM group (HR 5.94, p < 0.01]. Similar results were observed when adjusting for potential confounding variables. Conclusions: These results confirm that genetic changes are present in the apparently normal lung in many ADC patients, and this finding has prognostic implications. |
dc.format.mimetype |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
MDPI |
dc.relation.ispartof |
Journal of Clinical Medicine. 2019 Apr 17;8(4):529 |
dc.rights |
Copyright © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
dc.rights.uri |
http://creativecommons.org/licenses/by/4.0/ |
dc.title |
EGFR and KRAS mutations in the non-tumoral lung. Prognosis in patients with adenocarcinoma |
dc.type |
info:eu-repo/semantics/article |
dc.identifier.doi |
http://dx.doi.org/10.3390/jcm8040529 |
dc.subject.keyword |
Adenocarcinoma |
dc.subject.keyword |
EGFR |
dc.subject.keyword |
KRAS |
dc.subject.keyword |
Mutations |
dc.subject.keyword |
Prognosis |
dc.rights.accessRights |
info:eu-repo/semantics/openAccess |
dc.type.version |
info:eu-repo/semantics/publishedVersion |